Larry Carter, DO
Gastroenterology · Huntington, WVNPI 1285954669
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 36.5% of the total.
Across 128 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$843
- Johnson & Johnson$213
- Celltrion USA Inc.$210
- Takeda Pharmaceuticals U.S.A., Inc.$135
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$106
- Pfizer$79
- plus $725 from 23 others
What the payments were for
- Food & beverage$2,20996%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 59 | $843 |
| Johnson & Johnson(2 entities) | 5 | $213 |
| Celltrion USA Inc. | 5 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $135 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $106 |
| Pfizer | 5 | $79 |
| Redhill Biopharma Inc. | 5 | $69 |
| Ipsen Biopharmaceuticals, Inc | 2 | $59 |
| Gilead | 3 | $54 |
| Paratek Pharmaceuticals, Inc. | 3 | $54 |
| Intercept Pharmaceuticals, Inc. | 3 | $47 |
| Boehringer Ingelheim | 3 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Ferring Pharmaceuticals Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $34 |
| Novo Nordisk | 2 | $33 |
| Nestle Healthcare Nutrition Inc. | 1 | $30 |
| Ardelyx, Inc. | 2 | $29 |
| Philips North America LLC | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Sanofi | 1 | $19 |
| Organon | 1 | $17 |
| Amgen | 1 | $17 |
| Biogen | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Bristol Myers Squibb | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VEGZELMA$138
How this compares
$2,309 in reported general payments places this provider in the 60th percentile of 72 gastroenterology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 11 | $39,953 |
| LinzessLinaclotide | 20 | $23,863 |
| Mesalamine | 11 | $6,466 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 72 | $4,668 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 27 | $4,614 |
| Colestipol Hcl | 27 | $2,309 |
| Budesonide DrBudesonide | 17 | $2,059 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 87 | $1,330 |
| Pantoprazole Sodium | 99 | $1,137 |
| Omeprazole | 111 | $1,093 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 24 | $1,035 |
| Dicyclomine Hcl | 48 | $867 |
| Ondansetron OdtOndansetron | 24 | $388 |
| Ondansetron Hcl | 28 | $362 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 27 | $334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $106 | $39,95311 claims |
| AbbVieLinzess | $843 | $23,86320 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $35 | $4,61427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 72 gastroenterology providers in West Virginia.
Other gastroenterology in Huntington
- Wesam FrandahHuntington$28K
- Ahmed SherifHuntington$10K
- Matthew RohrbachHuntington$7K
- John EastoneHuntington$7K
- Charles HuhHuntington$7K
- Umapathy SundaramHuntington$5K
- Maen KamalHuntington$3K
- Pramod PantangiHuntington$3K
- Helgi SigmundssonHuntington$3K
- Adnan ElghezewiHuntington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.